Articles

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Nicholls SJ, Bhatt DL, Buse JB, et al.

First published: September 25, 2023  DOI: 10.1016/j.ahj.2023.09.007